Allena Pharmaceuticals, Inc. Debt/Equity

Debt/Equity of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending March 31, 2022 was 0.0 (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -100.0%
  • Annual Debt/Equity for 2021 was 0.55 (a 17.9% increase from previous year)
  • Annual Debt/Equity for 2020 was 0.47 (a -23.52% decrease from previous year)
  • Annual Debt/Equity for 2019 was 0.61 (a 202.33% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Allena Pharmaceuticals, Inc.

Most recent Debt/Equityof ALNA including historical data for past 10 years.

Interactive Chart of Debt/Equity of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0
2021 0.55 0.4 0.86 0.45 0.55
2020 0.47 0.55 0.45 0.88 0.47
2019 0.61 0.3 0.23 0.25 0.61
2018 0.2 0.17 0.15 0.06 0.2
2017 0.07 0.3 0.0 0.0 0.11
2016 0.0 0.26
2015 0.06 0.06

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.